Found this on GEN-03, the vaccine that couldn't fund the final trials. https://www.ncbi.nlm.nih.gov/pubmed/31103365?dopt=Abstract Seems like they are trying to find investors possibly. Does anyone have insight on this? I would love to have a series of vaccine shots versus a daily antiviral pill.
Clues to building a better herpes vaccine
by Ziba Kashef, Yale University
"Senior investigator Akiko Iwasaki and her colleagues conducted several experiments in mice vaccinated against the herpes simplex virus 2 (HSV-2). The researchers first found that the HSV-2 antibody the body produces in response to vaccination was not present in the vaginal cavity where it is most needed to protect against infection. They also learned that when specialized immune cells, called memory B cells, are physically drawn to the genital area, they produce and insert the antibody in the inner vaginal tissue. HavingBb I to the antibody circulating in the blood alone is not enough to protect against genital herpes infection, and a different strategy is needed to deliver the protective antibody in the future, Iwasaki said.
These results may explain why herpes vaccines that have been developed to date have not worked, say the researchers. The findings also support a different approach to vaccination, such as "prime and pull," which Iwasaki's lab has been investigating. This strategy involves combining conventional vaccination to trigger an immune response throughout the body (prime) and "c
hemokines," or signaling proteins, in vaginal tissue to attract another immune cell type, memory T cells, to the site where infection happens (pull). The team is currently working on establishing a successful prime-and-pull vaccine based on T cells and B cells."
Full paper here: https://www.sciencedirect.com/science/article/pii/S0264410X18315652
Note sure if anyone wrote about this. I couldn't find any results for VC2 in the site's search. This is a live attenuated vaccine from Louisiana State University. The results do not seem super promising, as reducing shedding/recurrance by < 70% pre-clinical is common in many discontinued vaccines. Still, research is being done, which is always great!
"Our studies also showed that VC2 vaccine decreases the clinical severity of acute and recurrent HSV-2 disease in guinea pigs when provided by intramuscular vaccination. During the primary infection, animals vaccinated with VC2 had a significant decrease in clinical severity and replicating virus in the vaginal vault. Prophylactic vaccination also decreased the quantity of virus in the DRGs when compared to the No Treatment group. The ability to protect neural tissue from latent infection probably contributed to the decrease in the number of animals with recurrent lesions by 67% and the number of days with recurrent vaginal shedding by 46%. This reduction in shedding is particularly important because transmission of HSV-2 to uninfected persons is largely due to asymptomatic shedding , ."
"When tested as a therapeutic vaccine, i.e., one designed to decrease recurrent disease and recurrent virus shedding in those already infected with HSV, the VC2 vaccine was not effective although it did reduce recurrent shedding, at least when compared to the gD2 vaccine. This may be because live attenuated vaccines have only limited replication in hosts that are already infected and thus do not have much of an impact in improving the immune response. Because infected hosts have frequent reactivations of virus that would be similar to a live vaccine inoculation it may be difficult for the vaccine to improve the immune response unless it is able to induce responses not activated by the host’s recurrent virus replication."
I'm sure a lot of you Google "hsv2-cure" daily like me. Looks like there may be a twinkle of hope. Not a cure, but at least some new news.
Found a good article what do you think ?